Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

HIV Infection

Free Subscription 16.09.2024 3 AIDS 2 BMJ 2 Cancer 1 Clin Infect Dis 3 HIV Med 18 J Acquir Immune Defic Syndr 1 J Clin Invest 2 J Infect Dis 1 J Med Virol 3 J Virol 1 MMWR Morb Mortal Wkly Rep 1 Nat Med 1 Pediatrics 1 PLoS Comput Biol 3 PLoS One 3 PLoS Pathog 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AIDS

1. KUNIHOLM MH, Murenzi G, Shumbusho F, Brazier E, et al
   Association of cardiovascular disease risk with liver steatosis and fibrosis in people living with hiv in low- and middle-income countries.
   AIDS. 2024 Sep 12. doi: 10.1097/QAD.0000000000004012.
   PubMed         Abstract available
   
   
2. SAHU M, Schaafsma T, Szpiro AA, Van Rooyen H, et al
   Performance of patient-collected dried blood spot specimens for HIV-1 viral load testing: evidence from the DO ART Study in South Africa.
   AIDS. 2024 Sep 13. doi: 10.1097/QAD.0000000000004011.
   PubMed         Abstract available
   
   
3. CUMMINGS TH, Magagnoli J, Sikirzhytskaya S, Tyagin I, et al
   Exposure to angiotensin-converting enzyme inhibitors that cross the blood-brain barrier and the risk of dementia among People Living with HIV.
   AIDS. 2024 Sep 10. doi: 10.1097/QAD.0000000000004009.
   PubMed         Abstract available
   
   

   
   BMJ

4. NAVARRO C, Lau C, Buchan SA, Burchell AN, et al
   Effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine against mpox infection: emulation of a target trial.
   BMJ. 2024;386:e078243.
   PubMed         Abstract available
   
   
5. DAL-RE R, Bekker LG, Jha V, Le Louarn A, et al
   Navigating US participant data sharing requirements: implications for international clinical trials.
   BMJ. 2024;386:e079701.
   PubMed        
   
   

   
   Cancer

6. MEGHANI K, Grover S
   Reply to "Assessing the impact of HIV status on cervical cancer treatment outcomes in Botswana: A commentary".
   Cancer. 2024 Sep 10. doi: 10.1002/cncr.35553.
   PubMed        
   
   
7. JEYARAJ G
   Assessing the impact of HIV status on cervical cancer treatment outcomes in Botswana: A commentary.
   Cancer. 2024 Sep 10. doi: 10.1002/cncr.35545.
   PubMed        
   
   

   
   Clin Infect Dis

8. VIDAL JE, Duarte AN, Chow FC, Duarte MIS, et al
   Does "Toxoplasma abscess" Properly Describe Brain Lesions Caused by Toxoplasma gondii?
   Clin Infect Dis. 2024 Sep 9:ciae463. doi: 10.1093.
   PubMed        
   
   

   
   HIV Med

9. 
   Correction to "Severe haematologic toxicity is rare in high risk HIV-exposed infants receiving combination neonatal prophylaxis".
   HIV Med. 2024 Sep 11. doi: 10.1111/hiv.13713.
   PubMed        
   
   
10. BARBER TJ, Clarke A, Fox A, Mackie NE, et al
    CROI 2024 BHIVA working group summary.
    HIV Med. 2024 Sep 10. doi: 10.1111/hiv.13705.
    PubMed         Abstract available
    
    
11. YANG X, Shi F, Zhang H, Giang WA, et al
    Long COVID among people with HIV: A systematic review and meta-analysis.
    HIV Med. 2024 Sep 10. doi: 10.1111/hiv.13708.
    PubMed         Abstract available
    
    

    
    J Acquir Immune Defic Syndr

12. WEIJSENFELD A, van der Knaap L, Sattoe J, van Staa A, et al
    Health-related quality of life in young adults with perinatal HIV after transfer to adult health care in the Netherlands.
    J Acquir Immune Defic Syndr. 2024 Sep 12. doi: 10.1097/QAI.0000000000003526.
    PubMed         Abstract available
    
    
13. REISNER SL, Humes E, Stevenson M, Cooney EE, et al
    Site-based and Digital Cohort Participation Among Transgender Women in the Eastern and Southern USA: Findings from the LITE Study.
    J Acquir Immune Defic Syndr. 2024 Sep 12. doi: 10.1097/QAI.0000000000003527.
    PubMed         Abstract available
    
    
14. 
    Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
    J Acquir Immune Defic Syndr. 2024;97:202.
    PubMed        
    
    
15. EL-HIBRI F, Al-Hindawi A, Singh S, Bower M, et al
    Outcomes of lymphoma patients admitted to the ICU are not influenced by HIV status: a retrospective, observational cohort study.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003522.
    PubMed         Abstract available
    
    
16. DEJESUS E, Towner WJ Jr, Gathe JC, Cash RB, et al
    Efficacy and safety of two fixed doses of ibalizumab plus optimized background regimen in treatment-experienced HIV-positive individuals.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003524.
    PubMed         Abstract available
    
    
17. BELL GJ, Chen JS, Maierhofer CN, Matoga M, et al
    Updated Risk Score Algorithms for Acute HIV Infection Detection at a Sexually Transmitted Infections Clinic in Lilongwe, Malawi.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003519.
    PubMed         Abstract available
    
    
18. MICHAEL HU, Brouillette MJ, Tamblyn R, Fellows LK, et al
    Disentangling the Effects of Comorbidity and Polypharmacy on Cognitive Function and Physical Frailty in Individuals with HIV.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003523.
    PubMed         Abstract available
    
    
19. YIGIT I, Budhwani H, Rainer CB, Claude K, et al
    Associations Between PrEP Stigma, PrEP Confidence, and PrEP Adherence: Conditional Indirect Effects of Anticipated HIV Stigma.
    J Acquir Immune Defic Syndr. 2024;97:99-106.
    PubMed         Abstract available
    
    
20. ORR JE, Velazquez J, Schmickl CN, Bosompra NO, et al
    Sleep, Sleep Apnea, and Fatigue in People Living With HIV.
    J Acquir Immune Defic Syndr. 2024;97:192-201.
    PubMed         Abstract available
    
    
21. LAZZARO A, Vai D, Barco A, Stroffolini G, et al
    Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
    J Acquir Immune Defic Syndr. 2024;97:180-191.
    PubMed         Abstract available
    
    
22. MASHETO G, Brummel SS, Ziemba L, Shepherd J, et al
    Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial.
    J Acquir Immune Defic Syndr. 2024;97:172-179.
    PubMed         Abstract available
    
    
23. DEBROY P, Barrett BW, Erlandson KM, Budoff M, et al
    Relationships Between Hepatic Steatosis and Frailty Differ by HIV Serostatus.
    J Acquir Immune Defic Syndr. 2024;97:165-171.
    PubMed         Abstract available
    
    
24. AOUIZERAT BE, Garcia JN, Domingues CV, Xu K, et al
    Frequent Cocaine Use is Associated With Larger HIV Latent Reservoir Size.
    J Acquir Immune Defic Syndr. 2024;97:156-164.
    PubMed         Abstract available
    
    
25. BELTRAN RM, Hunter LA, Packel LJ, De Martini L, et al
    A Mixed Methods Evaluation of Pharmacists' Readiness to Provide Long-Acting Injectable HIV Pre-exposure Prophylaxis in California.
    J Acquir Immune Defic Syndr. 2024;97:142-149.
    PubMed         Abstract available
    
    
26. MACGOWAN RJ, Chavez PR, Dana R, Hannah M, et al
    Efficacy of Internet Recruitment and HIV Self-Testing for Diagnosing HIV Infections Among Black and Hispanic/Latino MSM and Transgender Women in 11 US States, 2020-2021.
    J Acquir Immune Defic Syndr. 2024;97:133-141.
    PubMed         Abstract available
    
    
27. MUJUGIRA A, Karungi B, Nakyanzi A, Bagaya M, et al
    Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda: A Randomized Trial.
    J Acquir Immune Defic Syndr. 2024;97:125-132.
    PubMed         Abstract available
    
    
28. MCDONALD SA, Yeung A, Nandwani R, Clutterbuck D, et al
    A Statistical Model for Inference of Recent and Incident HIV Infection Using Surveillance Data on Individuals Newly Diagnosed With HIV Infection in Scotland.
    J Acquir Immune Defic Syndr. 2024;97:117-124.
    PubMed         Abstract available
    
    
29. YANG X, Zhang J, Chen S, Liu Z, et al
    COVID-19 Breakthrough Infections Among People With HIV: A Statewide Cohort Analysis.
    J Acquir Immune Defic Syndr. 2024;97:107-116.
    PubMed         Abstract available
    
    

    
    J Clin Invest

30. TRAVIESO T, Stadtler H, Alavian N, Gao F, et al
    Longitudinal analysis of viral dynamics in HIV+ to HIV+ HOPE Act kidney-transplant recipients.
    J Clin Invest. 2024 Sep 10:e181560. doi: 10.1172/JCI181560.
    PubMed         Abstract available
    
    

    
    J Infect Dis

31. NGUYEN HT, Chikata T, Zhang Y, Tran GV, et al
    Role of HLA-B*58:01-restricted CD8+ T cells in HIV-1 subtype AE infection.
    J Infect Dis. 2024 Sep 9:jiae448. doi: 10.1093.
    PubMed         Abstract available
    
    
32. SRINIVASAN S, Richardson BA, Wallis JM, Fiedler TL, et al
    Vaginal Bacteria and Proinflammatory Host Immune Mediators as Biomarkers of Human Immunodeficiency Virus Acquisition Risk Among African Women.
    J Infect Dis. 2024 Sep 9:jiae406. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Med Virol

33. GAY L, Desquiret-Dumas V, Nagot N, Rapenne C, et al
    Long-term persistence of mitochondrial dysfunctions after viral infections and antiviral therapies: A review of mechanisms involved.
    J Med Virol. 2024;96:e29886.
    PubMed         Abstract available
    
    

    
    J Virol

34. ZANKHARIA U, Yi Y, Lu F, Vladimirova O, et al
    HIV-induced RSAD2/Viperin supports sustained infection of monocyte-derived macrophages.
    J Virol. 2024 Sep 11:e0086324. doi: 10.1128/jvi.00863.
    PubMed         Abstract available
    
    
35. MARCHITTO L, Richard J, Prevost J, Tauzin A, et al
    The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity.
    J Virol. 2024 Sep 9:e0101624. doi: 10.1128/jvi.01016.
    PubMed         Abstract available
    
    
36. ZHANG S, Anang S, Zhang Z, Nguyen HT, et al
    Conformations of membrane human immunodeficiency virus (HIV-1) envelope glycoproteins solubilized in Amphipol A18 lipid-nanodiscs.
    J Virol. 2024 Sep 9:e0063124. doi: 10.1128/jvi.00631.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

37. BEER L, Tie Y, Crim SM, Weiser J, et al
    Progress Toward Achieving National HIV/AIDS Strategy Goals for Quality of Life Among Persons Aged >/=50 Years with Diagnosed HIV - Medical Monitoring Project, United States, 2017-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:781-787.
    PubMed         Abstract available
    
    

    
    Nat Med

38. JULG B, Walker-Sperling VEK, Wagh K, Aid M, et al
    Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.
    Nat Med. 2024 Sep 12. doi: 10.1038/s41591-024-03247.
    PubMed         Abstract available
    
    

    
    Pediatrics

39. DOMACHOWSKE J, Hamren UW, Banu I, Baronio R, et al
    Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children.
    Pediatrics. 2024 Sep 11:e2024066508. doi: 10.1542/peds.2024-066508.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

40. VEMPARALA B, Madelain V, Passaes C, Millet A, et al
    Antiviral capacity of the early CD8 T-cell response is predictive of natural control of SIV infection: Learning in vivo dynamics using ex vivo data.
    PLoS Comput Biol. 2024;20:e1012434.
    PubMed         Abstract available
    
    

    
    PLoS One

41. MERID F, Guyo TG, Wagaye S, Mekuria M, et al
    Uptake and associated factors of six multi-month scripting/appointment spacing differentiated service delivery model of care among stable clients on antiretroviral therapy in Southern Ethiopia.
    PLoS One. 2024;19:e0310400.
    PubMed         Abstract available
    
    
42. PALUPI S, Htet KKK, Nakhonsri V, Ngamphiw C, et al
    COVID-19's impact on hospital stays, mortality, and readmissions for poverty-related diseases, noncommunicable diseases, and injury groups in Thailand.
    PLoS One. 2024;19:e0310090.
    PubMed         Abstract available
    
    
43. JENNINGS K, Lembani M, Hesseling AC, Mbula N, et al
    A decline in tuberculosis diagnosis, treatment initiation and success during the COVID-19 pandemic, using routine health data in Cape Town, South Africa.
    PLoS One. 2024;19:e0310383.
    PubMed         Abstract available
    
    

    
    PLoS Pathog

44. CISNEROS WJ, Soliman SHA, Walter M, Simons LM, et al
    Release of P-TEFb from the Super Elongation Complex promotes HIV-1 latency reversal.
    PLoS Pathog. 2024;20:e1012083.
    PubMed         Abstract available
    
    
45. DESHPANDE A, Bryer AJ, Andino-Moncada JR, Shi J, et al
    Elasticity of the HIV-1 core facilitates nuclear entry and infection.
    PLoS Pathog. 2024;20:e1012537.
    PubMed         Abstract available
    
    
46. ALTMAN PX, Ozorowski G, Stanfield RL, Haakenson J, et al
    Immunization of cows with HIV envelope trimers generates broadly neutralizing antibodies to the V2-apex from the ultralong CDRH3 repertoire.
    PLoS Pathog. 2024;20:e1012042.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

47. BAKER RP, Liu AZ, Casadevall A
    Cell wall melanin impedes growth of the Cryptococcus neoformans polysaccharide capsule by sequestering calcium.
    Proc Natl Acad Sci U S A. 2024;121:e2412534121.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.